A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Bioanalytical methods quantify drugs and biomarkers in biological matrices (blood, plasma, urine) to support pharmacokinetics, bioavailability, and bioequivalence studies. LC-MS/MS is the gold standard owing to selectivity and sensitivity in complex matrices.
Your knowledge of HPLC and mass spectrometry prepared you for the instruments — bioanalytical methods apply those instruments to one of the most demanding analytical contexts imaginable. A blood sample is not a clean standard solution; it is a complex mixture of proteins, lipids, salts, metabolites, and cell debris, all present at concentrations vastly exceeding the drug you are trying to measure. The central challenge of bioanalysis is reliably quantifying nanogram-per-milliliter (or lower) drug concentrations in this overwhelming background.
Sample preparation is therefore the critical first step. Techniques like protein precipitation, liquid-liquid extraction, and solid-phase extraction remove matrix components that would otherwise suppress ionization, foul the column, or produce interfering signals. The choice of preparation method balances cleanup efficiency against analyte recovery — aggressive cleanup removes more interferences but may also lose analyte. For LC-MS/MS work, matrix effects (ion suppression or enhancement caused by co-eluting matrix components) are a persistent concern. You evaluate them by comparing analyte response in neat solvent versus in extracted matrix, and you mitigate them through better chromatographic separation, cleaner extraction, or stable isotope-labeled internal standards that experience the same suppression as the analyte.
The workhorse technique is LC-MS/MS operating in multiple reaction monitoring (MRM) mode. The first mass analyzer selects the precursor ion (the intact drug molecule), a collision cell fragments it, and the second mass analyzer monitors a specific product ion. This two-stage mass filtering provides extraordinary selectivity — even when chromatographic separation is imperfect, the probability that a matrix interference produces the same precursor-to-product transition at the same retention time is vanishingly small. This selectivity is why LC-MS/MS displaced older HPLC-UV methods for most pharmacokinetic applications.
Bioanalytical methods must meet stringent regulatory validation requirements defined by agencies like the FDA and EMA. Accuracy and precision are assessed at multiple concentration levels spanning the calibration range, including the lower limit of quantification (LLOQ) where the method's performance is weakest. Incurred sample reanalysis (ISR) — re-measuring a subset of actual study samples — verifies that the method performs as well on real patient samples as it did on spiked standards during validation. These regulatory frameworks exist because pharmacokinetic data directly inform dosing decisions: an inaccurate bioanalytical result can lead to an incorrect dose recommendation, with direct consequences for patient safety.